SCHEMBL5403231

SCHEMBL5403231

COc1ccc(CNC(=O)c2ccccc2-c2ccccc2C(=O)N(CCC(=O)O)Cc2ccc(F)cc2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 2/20 0.55
HDAC6 Q9UBN7 2/20 0.55
KCNK3 O14649 1/20 0.50
KCNK5 O95279 1/20 0.50
KCNA5 P22460 1/20 0.50
KCNK17 Q96T54 1/20 0.50
KCNK9 Q9NPC2 1/20 0.50
TDP1 Q9NUW8 1/20 0.48
RAB9A P51151 2/20 0.48
HPGD P15428 4/20 0.47
CYP1A2 P05177 1/20 0.47
CYP2C19 P33261 1/20 0.47
KMT2A Q03164 1/20 0.47
LPAR1 Q92633 1/20 0.46
MAPT P10636 2/20 0.46
THRB P10828 1/20 0.46
LMNA P02545 2/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
TP53 P04637 1/20 0.45
GLA P06280 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5402486 1.00 HDAC1 (0.55) HDAC1HDAC6KCNK3KCNK5KCNA5
SCHEMBL5403175 0.95 HDAC1 (0.59) HDAC1HDAC6TDP1RAB9AHPGD
SCHEMBL5397479 0.94 HDAC1 (0.61) HDAC1HDAC6TDP1RAB9AHPGD
SCHEMBL5407093 0.94 HDAC1 (0.61) HDAC1HDAC6TDP1RAB9AHPGD
SCHEMBL5407032 0.93 HDAC1 (0.51) HDAC1HDAC6KCNK3KCNK5KCNA5
SCHEMBL5402865 0.92 KMT2A (0.55) HDAC1HDAC6RAB9AHPGDCYP1A2
SCHEMBL5400829 0.92 KCNK3 (0.49) HDAC1HDAC6KCNK3KCNK5KCNA5
SCHEMBL5392370 0.91 HDAC1 (0.55) HDAC1HDAC6TDP1RAB9AHPGD
SCHEMBL5398638 0.91 KMT2A (0.54) HDAC1HDAC6RAB9AHPGDCYP1A2
SCHEMBL5399681 0.91 KMT2A (0.54) HDAC1HDAC6RAB9AHPGDCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7285680-B2 β-alanine derivatives and the use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2007-10-23 US disclosed
US-20050256160-A1 Beta-alanine derivatives and the use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2005-11-17 US disclosed
EP-1533294-A1 BETA-ALANINE DERIVATIVE AND USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2005-05-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050256160-A1 Beta-alanine derivatives and the use thereof TGFB1, PML, APOB HDAC1 2189/4885HDAC6 2386/4885KCNK3 4364/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.